keyword
MENU ▼
Read by QxMD icon Read
search

Phase 3 cancer

keyword
https://www.readbyqxmd.com/read/29913299/pharmacological-and-toxicological-study-of-a-chemical-standardized-ethanol-extract-of-the-branches-and-leaves-from-eysenhardtia-polystachya-ortega-sarg-fabaceae
#1
Angel Josabad Alonso-Castro, Juan Ramón Zapata-Morales, Victor Arana-Argáez, Julio Cesar Torres-Romero, Eyra Ramírez-Villanueva, Sabino Eduardo Pérez-Medina, Marco Antonio Ramírez-Morales, Mario Alberto Juárez-Méndez, Yessica Paola Infante-Barrios, Fidel Martínez-Gutiérrez, Candy Carranza-Álvarez, Mario Alberto Isiordia-Espinoza, Andrés Flores-Santos
Eysenhardtia polystachya is used for the empirical treatment of cancer, infections, diarrhea, inflammation, and pain. This study identified, using GC-MS, the main chemical components in an ethanol extract of E. polystachya branches and leaves (EPE) and tested its cytotoxic, antimicrobial, anti-diarrheal, anti-inflammatory, and antinociceptive effects. The in vitro and in vivo toxicity of EPE was evaluated using the comet assay in human peripheral blood mononuclear cells (PBMC) and the acute toxicity test in mice, respectively...
June 15, 2018: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29913254/patient-reported-outcomes-in-nrg-oncology-rtog-0938-evaluating-two-ultrahypofractionated-regimens-for-prostate-cancer
#2
Himanshu R Lukka, Stephanie L Pugh, Deborah W Bruner, Jean-Paul Bahary, Colleen A F Lawton, Jason A Efstathiou, Rajat J Kudchadker, Lee E Ponsky, Samantha A Seaward, Ian S Dayes, Darindra D Gopaul, Jeff M Michalski, Guila Delouya, Irving D Kaplan, Eric M Horwitz, Mack Roach, Wayne H Pinover, David C Beyer, John O Amanie, Howard M Sandler, Lisa A Kachnic
BACKGROUND: There is considerable interest in very short (ultrahypofractionated) radiotherapy regimens to treat prostate cancer based on potential radiobiological advantages, patient convenience and resource allocation benefits. OBJECTIVE: To demonstrate that detectable changes in health related quality of life measured by the bowel and urinary domains of the Expanded Prostate Cancer Index Composite (EPIC-50) were not substantially worse than baseline. DESIGN, SETTING, AND PARTICIPANTS: XXXX is a non-blinded randomized phase II study of NCCN low risk prostate cancer where each arm is compared to a historical control...
June 15, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29912271/randomized-phase-3-and-extension-studies-efficacy-and-impacts-on-quality-of-life-of-naldemedine-in-subjects-with-opioid-induced-constipation-and-cancer
#3
N Katakami, T Harada, T Murata, K Shinozaki, M Tsutsumi, T Yokota, M Arai, Y Tada, M Narabayashi, N Boku
Background: The efficacy and safety of naldemedine (a peripherally-acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase 3, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The primary endpoint, the proportion of spontaneous bowel movement (SBM) responders, was met. Here, we report results from secondary endpoints including quality of life (QOL) assessments from these studies...
April 18, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29910636/performance-status-dynamics-during-treatment-with-nab-paclitaxel-plus-gemcitabine-versus-gemcitabine-alone-for-metastatic-pancreatic-cancer
#4
E Gabriela Chiorean, Daniel Von Hoff, Yin Wan, Sandra Margunato-Debay, Marc Botteman, David Goldstein
Objectives: This analysis examined changes in Karnofsky performance status (KPS) as a surrogate for patient's well-being during treatment with nab -paclitaxel plus gemcitabine vs gemcitabine alone as first-line therapy for metastatic pancreatic cancer (MPC) in the Phase III MPACT trial. Participants and methods: Descriptive analyses were performed for KPS at three time points (3 and 6 months after randomization and 1 month before disease progression) and for time to any KPS deterioration...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29909889/gene-signatures-and-expression-of-mirnas-associated-with-efficacy-of-panitumumab-in-a-head-and-neck-cancer-phase-ii-trial
#5
Marco Siano, Vittoria Espeli, Nicolas Mach, Paolo Bossi, Lisa Licitra, Michele Ghielmini, Milo Frattini, Silvana Canevari, Loris De Cecco
OBJECTIVE: Platinum-based chemotherapy plus the anti-EGFR monoclonal antibody (mAb) cetuximab is used to treat recurrent/metastatic (RM) head-neck squamous cell carcinoma (HNSCC). Recently, we defined Cluster3 gene-expression signature as a potential predictor of favorable progression-free survival (PFS) in cetuximab-treated RM-HNSCC patients and predictor of partial metabolic FDG-PET response in an afatinib window-of-opportunity trial. Another anti-EGFR-mAb (panitumumab) was used as the treatment agent in RM-HNSCC patients in the phase II PANI01trial...
July 2018: Oral Oncology
https://www.readbyqxmd.com/read/29909581/switch-maintenance-therapy-with-docetaxel-and-bevacizumab-after-induction-therapy-with-cisplatin-pemetrexed-and-bevacizumab-in-advanced-non-squamous-non-small-cell-lung-cancer-a-phase-ii-study
#6
Koji Nishimoto, Masato Karayama, Naoki Inui, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Nao Inami, Shun Matsuura, Yusuke Kaida, Takashi Matsui, Kazuhiro Asada, Hiroyuki Matsuda, Masato Fujii, Mikio Toyoshima, Shiro Imokawa, Takafumi Suda
Switch maintenance therapy, using alternative agents that were not administered during induction chemotherapy, is a treatment option for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab is known to increase the efficacy of other chemotherapeutic agents; however, switch maintenance therapy with docetaxel and bevacizumab has not been adequately studied. The goal of this study was to evaluate the efficacy and safety of switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab...
June 16, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29908443/novel-pyrimidinic-selenourea-induces-dna-damage-cell-cycle-arrest-and-apoptosis-in-human-breast-carcinoma
#7
Flavio A R Barbosa, Tâmila Siminski, Rômulo F S Canto, Gabriela M Almeida, Nádia S R S Mota, Fabiana Ourique, Rozangela Curi Pedrosa, Antonio Luiz Braga
Novel pyrimidinic selenoureas were synthesized and evaluated against tumour and normal cell lines. Among these, the compound named 3j initially showed relevant cytotoxicity and selectivity for tumour cells. Three analogues of 3j were designed and synthesized keeping in view the structural requirements of this compound. Almost all the tested compounds displayed considerable cytotoxicity. However, 8a, one of the 3j analogues, was shown to be highly selective and cytotoxic, especially for breast carcinoma cells (MCF-7) (IC50  = 3...
June 11, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29908220/an-automated-multiparametric-mri-quantitative-imaging-prostate-habitat-risk-scoring-system-for-defining-external-beam-radiotherapy-boost-volumes
#8
Radka Stoyanova, Felix Chinea, Deukwoo Kwon, Isildinha M Reis, Yohann Tschudi, Nestor A Parra, Adrian L Breto, Kyle R Padgett, Alan Dal Pra, Matthew C Abramowitz, Oleksandr N Kryvenko, Sanoj Punnen, Alan Pollack
PURPOSE: To develop a prostate tumor habitat risk scoring (HRS) system based on multiparametric MRI (mpMRI) referenced to prostatectomy Gleason Score (GS) for automatic delineation of Gross Tumor Volumes (GTVs). A workflow for integration of HRS into radiotherapy (RT) boost volume dose escalation was developed in the framework of a Phase II randomized clinical trial (BLaStM). MATERIALS AND METHODS: An automated quantitative mpMRI based 10 point pixel by pixel method was optimized to prostatectomy GSs and volumes using referenced Dynamic Contrast Enhanced and Apparent Diffusion Coefficient sequences...
June 13, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29908105/phase-ii-trial-of-biweekly-cetuximab-and-irinotecan-as-third-line-therapy-for-pretreated-kras-exon-2-wild-type-colorectal-cancer
#9
Hiroki Osumi, Eiji Shinozaki, Tetsuo Mashima, Takeru Wakatsuki, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Yumiko Ota, Izuma Nakayama, Daisuke Takahari, Keisho Chin, Yoshio Miki, Kensei Yamaguchi
Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third-line treatment for pretreated metastatic colorectal cancer patients harboring wild-type KRAS Exon 2. Objective response rate was used as primary endpoint based on an expected proportion of 0.23 with confidence width of 0.298 (95% confidence interval, 0.105-0.403), which showed 35 to be the minimal participant number. Forty patients, refractory to first- and second-line chemotherapy containing irinotecan, oxaliplatin, and fluoropyrimidine were enrolled...
June 16, 2018: Cancer Science
https://www.readbyqxmd.com/read/29907593/the-role-of-pyruvate-dehydrogenase-kinase-4-pdk4-in-bladder-cancer-and-chemoresistance
#10
Benjamin L Woolbright, Dharamainder Choudhary, Andrew Mikhalyuk, Cassandra Trammel, Sambantham Shanmugam, Erika Abbott, Carol C Pilbeam, John A Taylor
Advanced bladder cancer (BCa) remains a major source of mortality, with poor treatment options. Cisplatin based chemotherapy is the standard treatment, however many patients are or become resistant. One potential cause of chemoresistance is the Warburg Effect, a metabolic switch to aerobic glycolysis that occurs in many cancers. Upregulation of the pyruvate dehydrogenase kinase family (PDK1-4) is associated with aerobic glycolysis and chemoresistance through inhibition of the pyruvate dehydrogenase complex (PDH)...
June 15, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29907553/development-and-evaluation-of-an-ethical-guideline-for-decisions-to-limit-life-prolonging-treatment-in-advanced-cancer-protocol-for-a-monocentric-mixed-method-interventional-study
#11
Katsiaryna Laryionava, Katja Mehlis, Elena Bierwirth, Friederike Mumm, Wolfgang Hiddemann, Pia Heußner, Eva C Winkler
BACKGROUND: Many patients with advanced cancer receive chemotherapy close to death and are referred too late to palliative or hospice care, and therefore die under therapy or in intensive care units. Oncologists still have difficulties in involving patients appropriately in decisions about limiting tumor-specific or life-prolonging treatment. OBJECTIVE: The aim of this Ethics Policy for Advanced Care Planning and Limiting Treatment Study is to develop an ethical guideline for end-of-life decisions and to evaluate the impact of this guideline on clinical practice regarding the following target goals: reduction of decisional conflicts, improvement of documentation transparency and traceability, reduction of distress of the caregiver team, and better knowledge and consideration of patients' preferences...
June 15, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29906734/clinical-consequences-of-chemotherapy-dose-reduction-in-obese-patients-with-stage-iii-colon-cancer-a-retrospective-analysis-from-the-petacc-3-study
#12
Gertraud Stocker, Ulrich T Hacker, Frédéric Fiteni, Jestinah John Mahachie, Arnaud D Roth, Eric Van Cutsem, Marc Peeters, Florian Lordick, Murielle Mauer
BACKGROUND: Dose reduction in obese cancer patients has been replaced by fully weight-based dosing recommendations. No data, however, are available on the effects of dose reduction in obese stage III colon cancer patients undergoing adjuvant chemotherapy. METHODS: Survival outcomes and toxicity data of obese (body mass index [BMI] ≥30 kg/m2 ), stage III colon cancer patients treated within the phase III PETACC 3 trial comparing leucovorin, 5-FU (LV5FU2) with LV5FU2 plus irinotecan were analysed retrospectively according to chemotherapy dosing at first infusion (i...
June 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29906251/randomized-double-blind-phase-ii-study-of-temozolomide-in-combination-with-either-veliparib-or-placebo-in-patients-with-relapsed-sensitive-or-refractory-small-cell-lung-cancer
#13
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto, Lihong Long, Lixia Diao, Jing Wang, Yevgeniva Bensman, Brenda Hurtado, Patricia de Groot, Erik P Sulman, Ignacio I Wistuba, Alice Chen, Martin Fleisher, John V Heymach, Mark G Kris, Charles M Rudin, Lauren Averett Byers
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2 /day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent...
June 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29905927/multicenter-randomized-double-blind-phase-2-trial-of-folfiri-with-regorafenib-or-placebo-as-second-line-therapy-for-metastatic-colorectal-cancer
#14
Hanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S Kasbari, Richard D Kim, Ray McDermott, Dominic T Moore, William Zamboni, William Grogan, Allen Lee Cohn, Tanios S Bekaii-Saab, Gregory Leonard, Theresa Ryan, Olugbenga O Olowokure, Nishan H Fernando, John McCaffrey, Bassel F El-Rayes, Anne M Horgan, Gary Bradley Sherrill, George Hosni Yacoub, Bert H O'Neil
BACKGROUND: Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double-blind, placebo-controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second-line treatment for metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer who progressed on first-line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland...
June 15, 2018: Cancer
https://www.readbyqxmd.com/read/29905784/blind-esophageal-brushing-offers-a-safe-and-accurate-method-to-monitor-inflammation-in-children-and-young-adults-with-eosinophilic-esophagitis
#15
Y Smadi, C Deb, J Bornstein, S Safder, K Horvath, D Mehta
Patients with eosinophilic esophagitis (EoE) require frequent evaluation of mucosal inflammation via endoscopy. Instead of endoscopy, mucosal evaluation in adults with esophageal cancer and candidiasis is achieved using a cytology brush inserted through a nasogastric tube (NGT). We conducted a prospective cross-sectional study in children and young adults scheduled for routine esophagogastroduodenoscopy (EGD) where in Phase 1, we performed esophageal brushing through the endoscope under direct visualization and in Phase 2, we inserted the brush through a Cortrak® NGT prior to endoscopy...
June 14, 2018: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/29905759/biomarker-assessment-of-the-cbcsg006-trial-a-randomized-phase-iii-trial-of-cisplatin-plus-gemcitabine-compared-with-paclitaxel-plus-gemcitabine-as-first-line-therapy-for-patients-with-metastatic-triple-negative-breast-cancer
#16
J Zhang, Y Lin, X J Sun, B Y Wang, Z H Wang, J F Luo, L P Wang, S Zhang, J Cao, Z H Tao, J Wu, Z M Shao, W T Yang, X C Hu
Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients...
June 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29905475/differential-effects-of-quercetin-and-its-two-derivatives-isorhamnetin-and-isorhamnetin-3-glucuronide-in-inhibiting-proliferation-of-human-breast-cancer-mcf-7-cells
#17
Qiu Wu, Paul A Kroon, Hongjun Shao, Paul W Needs, Xingbin Yang
Quercetin (Que) has consistently been reported to be useful cytotoxic compound in vivo and in vitro, but little is known on its metabolites. Here we examined and compared cytotoxic effect of Que and its water-soluble metabolites, isorhamnetin (IS) and isorhamnetin-3-glucuronide (I3G) in human breast cancer MCF-7 cells, and explain their tumor-inhibitory mechanism and structure-function relationship. The results showed that Que, IS and I3G could dose-dependently inhibit the growth of MCF-7 cells, and the cytotoxic effect was ranked as Que > IS > I3G...
June 15, 2018: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29905023/neoadjuvant-endocrine-therapy-with-exemestane-followed-by-response-guided-combination-therapy-with-low-dose-cyclophosphamide-in-postmenopausal-patients-with-estrogen-receptor-positive-breast-cancer-a-multicenter-open-label-phase-ii-study
#18
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Patients with estrogen receptor (ER)-positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone-sensitive patients. Most patients with ER-positive breast cancer are postmenopausal, and therefore, generally older and less able to tolerate chemotherapy. We aimed to investigate the efficacy and safety of tailored neoadjuvant endocrine and chemoendocrine therapy for postmenopausal breast cancer patients...
June 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29905018/phase-ii-study-of-carboplatin-pemetrexed-and-bevacizumab-in-advanced-nonsquamous-non-small-cell-lung-cancer
#19
Nicole F Laslett, SuJung Park, Gregory A Masters, David D Biggs, Charles J Schneider, Jamal G Misleh, Kathir Suppiah, Pamela S Simpson, Stephen Grubbs, Timothy F Wozniak, Michael Guarino
Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial looked to combine antiangiogenic therapy with a first-line cytotoxic chemotherapy doublet, hoping to extend median progression-free survival (PFS) while minimizing toxicity in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). In this single institution, single-arm study, 51 patients (age >18 yo) were followed from 2007 to 2012...
June 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29904817/optimization-of-temporal-sampling-for-18-f-choline-uptake-quantification-in-prostate-cancer-assessment
#20
Xavier Palard-Novello, Anne-Lise Blin, Florence Le Jeune, Etienne Garin, Pierre-Yves Salaün, Anne Devillers, Giulio Gambarota, Solène Querellou, Patrick Bourguet, Hervé Saint-Jalmes
BACKGROUND: Suboptimal temporal sampling of time-activity curves (TAC) from dynamic 18 F-fluoromethylcholine (FCH) PET images may introduce bias in quantification of FCH uptake in prostate cancer assessment. We sought to define an optimal temporal sampling protocol for dynamic FCH PET imaging. Seven different time samplings were tested: 5 × 60″, 10 × 30″, 15 × 15″-1 × 75″, 6 × 10″-8 × 30″, 12 × 5″-8 × 30″; 10 × 5″-4 × 10″-3 × 20″-5 × 30″, and 8 × 3″-8 × 12″-6 × 30″...
June 15, 2018: EJNMMI Research
keyword
keyword
17437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"